Market Pulse Archives

Nov. 18, 2021, 10:58 a.m. EST

Longeveron stock rockets on very heavy volume after upbeat FDA news

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Longeveron Inc. (LGVN)
  • X
    iShares Biotechnology ETF (IBB)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Longeveron Inc. /zigman2/quotes/224642771/composite LGVN 0.00% blasted 120.9% higher on very active morning trading Thursday, after the biotechnology company said its Lomecel-B for the treatment of a congenital heart defect in infants (Hypoplastic Left Heart Syndrome) affecting about 1,000 babies a year was granted rare pediatric disease (RPD) designation by the Food and Drug Administration. Trading volume exploded to 112.0 million shares, compared with the full-day average of about 110,000 shares. The stock was both the biggest gainer and most active on major U.S. exchanges. The company said Lomecel-B is currently being evaluated in a Phase 2 trial. Despite the rally, the stock, which went public in February, was still trading well below the initial public offering price of $10 a share. The stock has now climbed 77.7% over the past three months, while the iShares Nasdaq Biotechnology ETF /zigman2/quotes/206189322/composite IBB +1.15% has slipped 8.8% and the S&P 500 /zigman2/quotes/210599714/realtime SPX +1.00% has gained 6.4%.

/zigman2/quotes/224642771/composite
US : U.S.: Nasdaq
$ 7.42
0.00 0.00%
Volume: 89,015
Jan. 20, 2022 10:08a
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$165.13 million
Rev. per Employee
$189,737
loading...
/zigman2/quotes/206189322/composite
US : U.S.: Nasdaq
$ 133.35
+1.52 +1.15%
Volume: 319,926
Jan. 20, 2022 10:08a
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,578.23
+45.47 +1.00%
Volume: 387.35M
Jan. 20, 2022 10:09a
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.